Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia

Medical Hypotheses

Volumn 86, Issue , 2016, Pages 100-103

  Suppli, Malte P ^a   Lund, Asger ^a   Bagger, Jonatan I ^a   Vilsbøll, Tina ^a   Knop, Filip K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON;

ARTICLE; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PANCREAS ISLET ALPHA CELL; PATHOGENESIS; ANEMIA; BIOLOGICAL MODEL; COMPLICATION; FATTY LIVER; METABOLISM;

ANEMIA; DIABETES MELLITUS, TYPE 2; FATTY LIVER; GLUCAGON; GLUCAGON-SECRETING CELLS; HUMANS; MODELS, BIOLOGICAL;

EID: 84957547631     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.10.029     Document Type: Article

References (30)

1. Gromada J., Franklin I., Wollheim C.B. α-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007, 28(1):84-116.
2. Unger R., Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975, 305(7897):14-16.
3. Liljenquist J.E., Mueller G.L., Cherrington A.D., Keller U., Chiasson J.-L., Perry J.M., et al. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 1977, 59(2):369-374.
4. Mitrakou A., Kelley D., Veneman T., Jenssen T., Pangburn T., Reilly J., et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990, 39(11):1381-1390.
5. Knop F.K., Aaboe K., Vilsbøll T., Vølund A., Holst J.J., Krarup T., et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 2012, 14(6):500-510.
6. Færch K., Pilgaard K., Knop F.K., Hansen T., Pedersen O., Jørgensen T., et al. Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele. Diabetes Obes Metab 2013, 15(1):91-95.
7. Mitrakou A., Kelley D., Mokan M., Veneman T., Pangburn T., Reilly J., et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992, 326(1):22-29.
8. Lee Y., Wang M.-Y., Du X.Q., Charron M.J., Unger R.H. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011, 60(2):391-397.
9. Lee Y., Berglund E.D., Yu X., Wang M.-Y., Evans M.R., Scherer P.E., et al. Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells. Proc Natl Acad Sci 2014, 111(36):13217-13222.
10. Knop F.K., Vilsbøll T., Madsbad S., Holst J.J., Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007, 50(4):797-805.
11. Reaven G.M., Chen Y.D., Golay A., Swislocki A.L., Jaspan J.B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987, 64(1):106-110.
12. Shah P., Vella A., Basu A., Basu R., Schwenk W.F., Rizza R.A. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000, 85(11):4053-4059.
13. Kahn S.E., Prigeon R.L., McCulloch D.K., Boyko E.J., Bergman R.N., Schwartz M.W., et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993, 42(11):1663-1672.
14. Bugianesi, Elisabetta, Kalhan S., Burkett E., Marchesini G., McCullough A. Quantification of gluconeogenesis in cirrhosis: response to glucagon. Gastroenterology 1998, 115(6):1530-1540.
15. Petrides A.S., De Fronzo R.A. Failure of glucagon to stimulate hepatic glycogenolysis in well-nourished patients with mild cirrhosis. Metabolism 1994, 43(1):85-89.
16. Ørskov L., Alberti K.G.M.M., Mengel A., Møller N., Pedersen O., Rasmussen O., et al. Decreased hepatic glucagon responses in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991, 34(7):521-526.
17. Longuet C., Robledo A.M., Dean E.D., Dai C., Ali S., McGuinness I., et al. Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia evidence for a circulating α-cell growth factor. Diabetes 2013, 62(4):1196-1205.
18. Junker A.E., Gluud L.L., Hall G.V., Holst J.J., Knop F.K., Vilsbøll T. Effects of glucagon-like peptide-1 on glucagon secretion, endogenous glucose production, and whole body lipolysis in patients with nonalcoholic fatty liver disease. Diabetes 2015, 64(Supplement 1):A496-A574.
19. Charbonneau A., Couturier K., Gauthier M.-S., Lavoie J.-M. Evidence of hepatic glucagon resistance associated with hepatic steatosis: reversal effect of training. Int J Sports Med 2005, 26(6):432-441.
20. Charbonneau A., Unson C.G., Lavoie J.-M. High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise. J Physiol 2007, 579(1):255-267.
21. Charbonneau A., Melancon A., Lavoie C., Lavoie J.-M. Alterations in hepatic glucagon receptor density and in Gsα and Giα2 protein content with diet-induced hepatic steatosis: effects of acute exercise. Am J Physiol Endocrinol. Metab. 2005, 289(1):E8-14.
22. Jimba S., Nakagami T., Takahashi M., Wakamatsu T., Hirota Y., Iwamoto Y., et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005, 22(9):1141-1145.
23. Gupte P., Amarapurkar D., Agal S., Baijal R., Kulshrestha P., Pramanik S., et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004, 19(8):854-858.
24. Akbar D.H., Kawther A.H. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic prevalence and general characteristics. Diabetes Care 2003, 26(12):3351-3352.
25. Ferrannini E., Muscelli E., Natali A., Gabriel R., Mitrakou A., Flyvbjerg A., et al. Association of fasting glucagon and proinsulin concentrations with insulin resistance. Diabetologia 2007, 50(11):2342-2347.
26. Ezzat W.M., Ragab S., Ismail N.A., Elhosary Y.A., ElBaky A.M.N.E.A., Farouk H., et al. Frequency of non-alcoholic fatty liver disease in overweight/obese children and adults: Clinical, sonographic picture and biochemical assessment. J Genet Eng Biotechnol 2012, 10(2):221-227.
27. Miller R.A., Chu Q., Xie J., Foretz M., Viollet B., Birnbaum M.J. Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP. Nature 2013, 494(7436):256-260.
28. MacDonald P.E., El-kholy W., Riedel M.J., Salapatek A.M.F., Light P.E., Wheeler M.B. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002, 51(Suppl. 3):S434-S442.
29. Ahrén B., Landin-Olsson M., Jansson P.-A., Svensson M., Holmes D., Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004, 89(5):2078-2084.
30. Ferrannini E., Muscelli E., Frascerra S., Baldi S., Mari A., Heise T., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014, 124(2):499-508.